Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

459
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
459
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

536
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
536
Glaucoma: Overview01:25

Glaucoma: Overview

599
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
599

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger.

PLOS global public health·2026
Same author

Predictors of home- vs. facility-based delivery among women living in rural Niger: a cross-sectional survey within the AVENIR cluster-randomised trial.

Journal of global health·2026
Same author

Azithromycin mass drug administration to reduce child mortality in Niger (AVENIR II): a master protocol for a cluster-randomized adaptive platform trial to evaluate community-based health interventions.

Trials·2026
Same author

Mass Azithromycin Distributions and Childhood Clinic Visits in Niger: A Community-Randomized Trial.

The American journal of tropical medicine and hygiene·2025
Same author

Spillover of Azithromycin Mass Drug Administration and Child Survival: A Secondary Analysis of a Cluster-Randomized Clinical Trial.

JAMA network open·2025
Same author

Characterizing trachoma elimination using serology.

Nature communications·2025

Related Experiment Video

Updated: Jul 13, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K

Micropulse diode laser therapy in refractory glaucoma.

Moctar Issiaka1, Khalil Zrikem1, Adil Mchachi2,1

  • 1Adult Ophthalmology Department, 20 August 1953 Hospital, Ibn Rochd University Hospital of Casablanca, Casablanca, Morocco.

Advances in Ophthalmology Practice and Research
|October 17, 2023
PubMed
Summary
This summary is machine-generated.

Micropulse transscleral cyclophotocoagulation is a safe and effective treatment for refractory glaucoma, significantly reducing intraocular pressure. This study suggests broadening its use for better patient outcomes.

Keywords:
Intraocular pressureMicropulse laserRefractory glaucomaTransscleral cyclophotocoagulation

More Related Videos

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

15.0K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 4, 2007

11.4K

Related Experiment Videos

Last Updated: Jul 13, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K
Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

15.0K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 4, 2007

11.4K

Area of Science:

  • Ophthalmology
  • Medical Technology

Background:

  • Refractory glaucoma presents a significant challenge in intraocular pressure (IOP) management.
  • Traditional treatments may be insufficient for advanced or complex glaucoma cases.

Purpose of the Study:

  • To evaluate the safety and efficacy of micropulse transscleral cyclophotocoagulation (MP-TSCPC) for refractory glaucoma.
  • To assess the impact of MP-TSCPC on IOP and medication usage in diverse glaucoma subtypes.

Main Methods:

  • A prospective study involving 39 eyes of 31 patients with refractory glaucoma.
  • Treatment with the Iridex Cyclo G6 laser and Micropulse P3 probe (810 nm wavelength).
  • Parameters: 90s duration, 2000 mW power, 180 J energy per hemisphere, sparing 3 and 9 o'clock meridians.

Main Results:

  • Mean preoperative IOP of 42.3 mmHg reduced to 16.9 mmHg at 9 months (49.9% reduction).
  • Average medication use decreased from four to two drugs, with 70.3% on dual therapy at 9 months.
  • Overall success rate was 60.5%, with good ocular pain and tolerance reported.

Conclusions:

  • Micropulse transscleral cyclophotocoagulation demonstrates significant safety and efficacy in treating refractory glaucoma.
  • The study supports expanding the indications for MP-TSCPC, proposing its earlier consideration in various glaucoma scenarios.